Search research articles
Contact Us
Filters
Showing results (881-890 of 973) with videos related to
Page
of 98
Sort By:
Nature Reviews. Neurology
|
June 13, 2023
Cognitive impairment in people living with HIV: consensus recommendations for a new approach
Sam Nightingale, Beau Ances, Paola Cinque, et al.
Journal of Virus Eradication
|
October 27, 2016
Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA
Jeymohan Joseph, Paola Cinque, Deborah Colosi, et al.
Journal of Materials Chemistry. B
|
December 5, 2024
PEGylation of indium phosphide quantum dots prevents quantum dot mediated platelet activation
Leigh Naylor-Adamson, Thomas W Price, Zoe Booth, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 6, 2008
BRI2 (ITM2b) inhibits Abeta deposition in vivo
Jungsu Kim, Victor M Miller, Yona Levites, et al.
Medicine
|
November 19, 2015
Centralized HIV Program Oversight: An Investigation of a Case Series of New HIV Infections among US Army Soldiers, 2012 to 2013
Laura A Pacha, Shilpa Hakre, Otha Myles, et al.
JAMA Ophthalmology
|
October 17, 2025
Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study: A Randomized Clinical Trial
Jonathan H Lass, Beth Ann Benetz, David D Verdier, et al.
HIV Clinical Trials
|
June 13, 2008
Determination of the underlying cause of death in three multicenter international HIV clinical trials
Alan R Lifson, , Waldo H Belloso, et al.
Journal of Medicinal Chemistry
|
May 9, 1998
The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo
L M Gaster, F E Blaney, S Davies, et al.
AIDS (London, England)
|
February 10, 2018
No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts
Edwina J Wright, Birgit Grund, Kevin R Robertson, et al.
Neurology
|
October 5, 2007
Updated research nosology for HIV-associated neurocognitive disorders
A Antinori, G Arendt, J T Becker, et al.
Page
of 98
Search research articles
Search
Showing results (881-890 of 973) with videos related to
Sort By:
Page
of 98
Nature Reviews. Neurology
|
June 13, 2023
Cognitive impairment in people living with HIV: consensus recommendations for a new approach
Sam Nightingale, Beau Ances, Paola Cinque, et al.
Journal of Virus Eradication
|
October 27, 2016
Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA
Jeymohan Joseph, Paola Cinque, Deborah Colosi, et al.
Journal of Materials Chemistry. B
|
December 5, 2024
PEGylation of indium phosphide quantum dots prevents quantum dot mediated platelet activation
Leigh Naylor-Adamson, Thomas W Price, Zoe Booth, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 6, 2008
BRI2 (ITM2b) inhibits Abeta deposition in vivo
Jungsu Kim, Victor M Miller, Yona Levites, et al.
Medicine
|
November 19, 2015
Centralized HIV Program Oversight: An Investigation of a Case Series of New HIV Infections among US Army Soldiers, 2012 to 2013
Laura A Pacha, Shilpa Hakre, Otha Myles, et al.
JAMA Ophthalmology
|
October 17, 2025
Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study: A Randomized Clinical Trial
Jonathan H Lass, Beth Ann Benetz, David D Verdier, et al.
HIV Clinical Trials
|
June 13, 2008
Determination of the underlying cause of death in three multicenter international HIV clinical trials
Alan R Lifson, , Waldo H Belloso, et al.
Journal of Medicinal Chemistry
|
May 9, 1998
The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo
L M Gaster, F E Blaney, S Davies, et al.
AIDS (London, England)
|
February 10, 2018
No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts
Edwina J Wright, Birgit Grund, Kevin R Robertson, et al.
Neurology
|
October 5, 2007
Updated research nosology for HIV-associated neurocognitive disorders
A Antinori, G Arendt, J T Becker, et al.
Page
of 98